pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·Jun 20·1 min read
save

STAT invites reader debate on blue zones and open-access publishing fees

Jun 20, 2026·read at STAT ↗Neutral

Torie Bosch, editor of STAT’s First Opinion platform, has published an opinion piece encouraging readers to submit letters responding to recent essays.

The article explains that STAT will publish selected letters to foster good‑faith discussion, and provides a link for submissions at the end of each First Opinion essay.

Among the topics highlighted for debate are the reality of so‑called blue zones and the cost of open‑access publishing fees, with Bosch noting her two‑decade experience covering blue zones for National Geographic.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “Opinion: STAT readers debate blue zones, open-access publishing fees, and more”

read at STAT ↗
3,452 words · retrieved Jun 20
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
LEADINGUniversity of IowaWM TECHNOLOGY, INC.
topics
ImmunologyOncologyPlatform CompanyType 2 Diabetes

related stories

  • Dec 22Fierce Biotech Fundraising Tracker '26: Superluminal snags $60M; AusperBio adds $120MFierce Biotech
  • 3d agoA winner, a loser, and a mid-stage signal from a major cardiology research conferenceSTAT
  • Jun 2910 clinical trials to watch in the second half of 2026BioPharma Dive
  • May 13How Reimagined Research Endeavors Intersect With Dignified End-of-Life Care: With D. Ross Camidge, MD, PhD; and Charles D. Blanke, MD, FACP, FASCOonclive
  • May 12GU Cancer Experts Highlight Top Abstracts to Watch During ASCO 2026onclive